Nitric oxide (NO) is the principal mediator of penile erection. NO is synthesized by a variety of nitric oxide synthases (NOS). It has been demonstrated that a decrease in NOS activity, as observed in aging, is associated with a diminished erectile response. The objective of this study was to determine if adenoviral-mediated gene transfer of eNOS could reverse age-related erectile dysfunction in the rat. Two groups of animals were transfected with adenoviruses: (1) aged rats (60 weeks) with AdRSVbgal; and (2) aged rats (60 weeks) with AdRSVeNOS. Five days after transfection, these study animals underwent cavernosal nerve stimulation (CNS) to assess erectile function and their responses were compared with young (20 weeks) control rats. Cross-sections of the rat penises transfected with AdRSVeNOS were examined after trichrome staining. Adenoviral transduction ef®ciency of b-galactosidase reporter gene was measured by a galacto-light chemiluminescent reporter gene assay in cavernosal tissues of rats administered AdRSVbgal. The transgene expression of eNOS was examined by RT-PCR in rats transfected with AdRSVbgal and AdRSVeNOS. eNOS and iNOS protein levels were measured by Western blot analysis, and cGMP levels were assessed in cavernosal tissue by enzyme immunoassay. Adenoviral expression of the b-galactosidase reporter gene was observed in cavernosal tissue for up to 30 days, with peak expression registered at 5 days after intracavernosal administration of AdRSVbgal. Cross-sections of the rat penises transfected with the AdRSVeNOS revealed no pathological (morphological or histological) changes. Five days after administration of AdRSVeNOS, eNOS protein, mRNA and cGMP levels in the corpora cavernosa were signi®cantly increased (P`0.05), while iNOS protein levels remained unchanged (P b 0.05). In conclusion, enhanced expression of eNOS employing an adenoviral vector signi®cantly increased the erectile response to cavernosal nerve stimulation in the aged rat, similar to the response observed in younger rats. These data suggest that in vivo adenoviral gene transfer of eNOS can physiologically improve erectile function in the aged rat.
Introduction
Male erectile dysfunction (ED) has been de®ned as the inability to attain andaor maintain penile erection suf®cient for satisfactory sexual performance. ED af¯icts approximately 20 ± 30 million men in the United States and is caused in part by inadequate relaxation of the corpora cavernosal smooth musculature. 1, 2 Major risk factors for ED include aging, diabetes, Peyronie's disease, hypertension and extirpative pelvic surgery.
Nitric oxide (NO) is recognized to be the principal mediator of penile erection. 3, 4 NO is synthesized from L-arginine by a family of enzymes called NO synthases (NOS). The three different isoforms of NOS in the penis are endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). The constitutive forms of NOS, eNOS and nNOS are regulated by intracellular Ca 2¯u xes that permit calmodulin binding and enzyme activation. 5 In contrast, iNOS is transcriptionally regulated and is generally believed to be expressed in response to cellular stress and upregulated in pathophysiological conditions. 5, 6 NO derived from nNOS is released from non-adrenergic, non-cholinergic (NANC) nerves, while NO from eNOS is released from the trabecular endothelium and diffuses into the smooth muscle cells where it directly interacts with the soluble form of guanylate cyclase to increase intracellular levels of cyclic GMP (cGMP) and cause penile smooth muscle relaxation. 7 A decrease in erectile function can be attributed to a decrease in NO synthesis in the NANC penile nerve ®bers or vascular endothelium of the penis. 8 A number of investigators have reported a reduction in NOS activity in aged, diabetic and androgendepleted rats. 9 ± 13 In theory, replacement of NOS can be accomplished by employing gene transfer of exogenous NOS to the corpora cavernosa of the penis. The penis is an ideal organ for gene therapy because of its external location and slow circulation. 14, 15 Christ and colleagues reported that injecting cDNA encoding hSlo, a maxi-K channel, increased gap junction formation and enhanced erectile responses to nerve stimulation in aged rats. 14 Garban and colleagues injected cDNA encoding RPiNOS into the corpus cavernosum of the aged rat and reversed age-related erectile dysfunction. 16 This study provided evidence that in vivo gene transfer of NOS isoforms can have physiologically bene®cial consequences on failing erections in aged rats. Recently, our lab demonstrated enhanced erectile response to cavernosal nerve stimulation in aged rats after adenoviral gene transfer of eNOS. 17 However, in this study, the expression of eNOS in the penis was limited to only 5 days. In the present study, our aim was to investigate the effect of adenoviral gene transfer of eNOS using a different promoter which exhibits a longer duration of expression of eNOS.
Materials and methods

Adenovirus vectors
Two replication-de®cient recombinant adenoviruses, serotype 5-encoding nuclear-targeted bgalactosidase (AdRSVbgal) and eNOS (AdRSVeNOS), both driven by a rous sarcoma (RSV) promotor, were prepared as previously described. 18 AdRSVbgal was used as a control virus. Recombinant adenoviruses were plaque puri®ed to assure that viral suspensions were free of wild-type virus, and titers were determined by plaque assay on 293 cells. After puri®cation, the virus was suspended in phosphate buffer saline (PBS) with 3% sucrose and kept at À70 C until use. Ampli®cation and puri®ca-tion were performed by the University of Iowa Gene Transfer Vector Core, Iowa City, IA.
In vivo gene delivery to the corpora cavernosa
Sixty-week-old male Sprague ± Dawley rats weighing 475 ± 550 g were anesthetized with sodium pentobarbital (30 mgag i.p.) and placed in a supine position on a thermoregulated surgical table. Body temperature was maintained at 37 C with a water jacketed heating blanket. Using sterile technique, the penis was exposed. Using a 30-gauge needle attached to a microliter syringe, 20 ml of vehicle (3% sucrose in PBS), AdRSVbgal (1Â10 12 partsaml) or AdRSVeNOS (1Â10 12 partsaml) was injected into the corpus cavernosum. Immediately before instillation, blood drainage via the dorsal veins was halted by circumferential compression at the base of the penis with an elastic band. Compression was released 5 min after injection of 20 ml of the vehicleavirus.
Expression of b-galactosidase in cavernosal tissue
Two to 35 days after adenovirus administration, the rats were anesthetized with pentobarbital (30 mgag i.p.) and placed in a supine position on a surgical table. Rats did not show any overt signs of systemic (fever, dyspnea, tachycardia) or local (purulent discharge, erythema, edema) infection when observed any day after transfection. The rats were sacri®ced with an overdose of pentobarbital (80 mgakg i.p.) and the penises were removed. Expression of b-galactosidase was evaluated by measurement of b-galactosidase activity in cavernosal tissue samples.
For determination of b-galactosidase activity (Galacto-Light Plus, Tropix, Bedford, MA), the penile corpus cavernosum tissues were homogenized for 20 s in a Tissumizer (Tekmar Co.) in 500 ml of the following TMNC buffer: 50 mM Tris, pH 7.5, 5 mM MgCl 2 , 100 mM NaCl and 4% (wtavol) 3-[(cholamidopropyl) dimethyl ammonio] 1-propanesulfonate (CHAPS). Samples were centrifuged (12,000 rpm; 10 min), and the supernatant was removed. Original and dilutions (1 : 10 and 1 : 100) were prepared in duplicate for each tissue lysate. Aliquots of tissue lysate were assayed for b-galactosidase activity with 3-(4-methoxyspirol-[1,2dioxe-tane-3,2 1 -tricyclo-[3.3.1.1 3, 7 ]decan]-4-yl)-phenyl-b-D-galactopyraniside. Light emission was measured with a luminometer (Luminoscan RS, Labsystems, Franklin, MA) and calibrated with a standard curve generated with the use of puri®ed Escherichia coli bgalactosidase. Protein concentrations of the samples were determined (BioRad DC Protein Assay, BioRad Laboratories, Hercules, CA), and normalized bgalactosidase activity was expressed as relative light units of b-galactosidase per milligram protein.
Trichrome stain
Five days after transfection with vehicle and AdRSVeNOS, the rat penises underwent histological examination using Masson's trichrome stain. Each rat penis was ®xed in neutral buffered 10% formalin and processed for paraf®n embedding. Five micron-thick tissue sections were applied to charged slides, deparaf®nized and hydrated with distilled water. The sections were then stained with Masson's trichrome stain, which determines the relative proportion of collagen to stromal smooth muscle, as previously described. 19 Western blot analysis Expression of eNOS, iNOS and a-actin in rat cavernosal tissue was assessed 5 days after intracavernosal injection of vehicle, AdRSVbgal and AdRSVeNOS. To extract total protein, cavernosal tissue was homogenized (Polytron, Brinkmann Instruments, Westbury, NY) in ice-cold buffer (Hepes 5 mM, pH 7.9, glycerol 26%, MgCl 2 1.5 mM, EDTA 0.2 mM, DTT 0.5 mM, phenylmethylsulfonyl¯uoride 0.5 mM) with NaCl (300 mM ®nal) and incubated on ice for 30 min. After centrifugation twice at 15,000 g and 4 C for 20 min, protein concentration was determined by using a BioRad DC protein assay (BioRad, Hercules, CA), and the samples were stored at À70 C until use. For Western blot analysis, the supernatant was mixed with an equal volume of 2% SDSa1%-b-mercaptoethanol and fractionated using 8% SDS ± PAGE (70 mgalane). Proteins were then transferred to a nitrocellulose membrane (Hybond-ECL, Amersham Life Sciences, Ghent, Belgium) by semi-dry electroblotting for 1 h. The membranes were blocked for 1 h at room temperature with blotto-Tween (5% nonfat dry milk, 0.1% Tween-20) and incubated with primary monoclonal rat anti-eNOS lgG or iNOS lgG antibodies (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA). Bound antibody was detected with labeled rabbit anti-rat lgG secondary antibody (1 : 20,000, Santa Cruz Biotechnology, Santa Cruz, CA) and visualized using enhanced chemiluminescence.
RNA extraction and RT-PCR ampli®cation
Total RNA was isolated from the corpus cavernosum of animals 5 days after transfection with vehicle, AdRSVbgal and AdRSVeNOS using 1 ml of TRI Reagent (Molecular Research Center, Inc.) and prepared for RT-PCR. Total RNA (2 mg) was primed with random hexadeoxynucleotides (0.2 mg; Promega, Madison, WI) and reverse-transcribed with MMLV RT (100 U; Life Technologies Inc. Gaithersburg, MD) in the presence of RNasin (20 units; Promega) in a 20 ml total reaction volume. The polymerase chain reaction (PCR) were performed in a total volume of 25 ml containing 200 mmolal dNTPs, 6 ml of RT reaction mixture (4 ml for b-actin), 22 U recombinant Taq DNA polymerase, and 20 mM of the speci®c primer pairs for eNOS or b-actin. The PCR reactions were cycled 35 times between 94 C (denaturation) for 1 min; 60 C (annealing) for eNOS and b-actin for 1 min; and 72 C (extension) for 1 min. Samples were incubated at 72 C for an additional 7 min after the last cycle was completed.
All nucleotide primers were purchased from Integrated DNA Technologies Inc. (Coralville, IA). The primer pairs were chosen from the published cDNA sequences of rat eNOS (19; U02543) and human b-actin (7; X00351), as previously described. 20 All primer pairs spanned at least one intron in the genomic DNA sequence. The primer sequence for eNOS corresponds to 5
H -CTG CTG CCC GAG ATA TCT TC-3 H (sense, bp 255 ± 274) and 5 H -CAG GTA CTG CAG TCC CTC CT-3 H (antisense, bp 482 ± 465); the ®nal PCR product was 230 bp in size. Oligonucleotide primers for b-actin (sense, 5
H -AAC CGC GAG AAG ATG ACC CAG ATC ATG TTT-3 H ; and antisense, 5
H -AGC AGC CGT GGC CAT CTC TTG CTC GAA GTC-3 H ) were used as a positive control in each sample, as previously described. 20 The PCR products were separated on a 2% agarose gel in 0.5 Â Tris-borate-EDTA (TBE) buffer (10 Vacm gel length for 1.5 h), stained with ethidium bromide (0.5 mgaml), visualized under ultraviolet light, and quantitated by densitometric analysis.
Measurement of cavernosal tissue cGMP levels
Five days after instillation of vehicle, AdRSVbgal or AdRSVeNOS, corpus cavernosal tissue was rinsed with PBS, quick frozen in liquid nitrogen and stored at À70 C until determination of cGMP levels. Whole corpus cavernosum tissue was homogenized in 1 ml ice-cold 6% trichloroacetic acid (TCA), pH 4.0. Each sample was then centrifuged at 1500 g for 10 min at 4 C. The supernatant was transferred to a 10 ml test tube, and the TCA was extracted with H 2 O saturated diethyl ether. The samples were assayed for cGMP using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI). Cavernosal cGMP levels are expressed as femtomoles cGMP per mg of protein.
Measurement of erectile responses
Twenty-week-old Sprague ± Dawley rats and 60-week-old Sprague ± Dawley rats were employed in The bladder and prostate were exposed through a midline abdominal incision. The cavernosal nerve was identi®ed posterolateral to the prostate on one side, and an electrical stimulator with a stainless steel bipolar hook was placed around the cavernosal nerve. The skin overlying the penis was incised and the right crura was exposed by removing part of the overlying ischiocavernous muscle. A 25-G needle ®lled with 250 Uaml of heparin and connected to PE-50 tubing was inserted into the right crura. A 30-G needle connected to PE-10 tubing was placed in the left corpus cavernosum for administration of drugs into the penis. Systemic arterial and intracavernosal blood pressure were measured with a statham P23 pressure transducer connected to a computerized system for data acquisition (DATAQ, Data Systems International, St Paul, MN). The cavernosal nerve was stimulated with a square pulse stimulator (Grass Instruments). Each rat was submitted to electrical ®eld stimulation (EFS) at a frequency of 15 Hz, pulse width 30 s, and duration of 1 min. The application of 5 and 7.5 V was used in the current protocol to achieve a signi®cant and consistent erectile response. These procedures have been previously described. 14,21
Statistics
The hemodynamic data are expressed as mean AE s.e. and were analyzed using a one-way analysis of variance (ANOVA) with repeated measures and Neumann ± Kuels post hoc test for multiple group comparisons. A P value of less than 0.05 was used as the criterion for statistical signi®cance.
Results
In Figure 1 ). b-galactosidase activity was signi®cantly (P`0.05) higher in cavernosal tissue of those animals transfected with AdRSVbgal for up to 30 days (Figure 1 ). Penile tissue from rats which were treated with vehicle or AdRSVeNOS showed very low levels of b-galactosidase activity (1392 AE 21 RLUamg protein).
Protein analysis of eNOS and iNOS and measurement of cGMP eNOS and iNOS protein levels were measured in cavernosal tissue 5 days after intracavernosal administration of vehicle, AdRSVbgal, or AdRSV eNOS gene transfer to the penis TJ Bivalacqua et al eNOS, and these data are summarized in Figure 2 . Five days after transfection with the adenovirus encoding for the eNOS gene (AdRSVeNOS), eNOS protein levels (135 kDa) in cavernosal tissue were signi®cantly (P`0.05) higher (Figure 2, lane 3 ) when compared to animals transfected with vehicle or AdRSVbgal (Figure 2, lanes 1 and 2) . When eNOS levels were analyzed by densitometry and expressed per mg protein, eNOS protein levels were signi®-cantly greater in rats after transfection with AdRSVeNOS when compared to eNOS protein levels in rats treated with vehicle or AdRSVbgal (Figure 2) . Because adenoviral genes have been shown to cause host-in¯ammatory responses, Western blot analysis for iNOS (120 kDa) was performed in cavernosal tissue after transfection with vehicle and the adenoviral genes encoding b-galactosidase and eNOS. There was no statistical difference in protein expression for iNOS between the vehicle-, AdRSVbgal-and AdRSVeNOS-transfected groups ( Figure 2, lanes 1 ± 3) . When iNOS levels were analyzed by densitometry and expressed per mg protein, iNOS protein levels were similar in all animals ( Figure 2 ). Levels of a-actin protein (42 kDa) were similar in cavernosal tissue harvested from vehicle-, AdRSVbgal-and AdRSVeNOS-transfected rats (Figure 2 ). These results with protein expression for eNOS, iNOS and a-actin in cavernosal tissue of vehicle-, AdRSVbgal-and AdRSVeNOS-treated animals are typical of 8 ± 10 independent observations. Cavernosal tissue concentrations of cGMP were measured 5 days after intracavernosal administration of vehicle, AdRSVbgal or AdRSVeNOS, and these data are summarized in Figure 3 . Cavernosal cGMP was similar in cavernosal tissue of rats transfected with vehicle or AdRSVbgal (Figure 3) . cGMP concentrations were signi®cantly increased (P`0.05) in cavernosal tissue of rats transfected with AdRSVeNOS when compared to animals transfected with vehicle or AdRSVbgal (P`0.05; Figure 3 ).
Semiquantitative RT-PCR for eNOS
Five days after transfection with vehicle, AdRSbgal or AdRSVeNOS, eNOS and b-actin mRNA expression was determined in cavernosal tissue from all groups. The mRNA for eNOS (230 bp) was expressed in cavernosal tissue from all three groups of animals and was signi®cantly higher in animals transfected with AdRSVeNOS when compared to vehicle-or AdRSVbgal-treated animals ( Figure 4A ). As a positive control for RNA extraction and the RT reaction, the b-actin product was detected in 
In vivo gene transfer of AdRSVeNOS and erectile function
The effect of cavernosal nerve stimulation on the erectile function in vivo was measured to evaluate the physiological relevance of overexpression of the eNOS gene via adenoviral gene transfer of eNOS to the corpus cavernosum of aged rats. In order to conduct these studies, the rats were divided into three groups: (1) young rats (20 weeks); (2) aged rats (60 weeks) transfected with AdRSVbgal; and (3) aged rats (60 weeks) transfected with AdRSVeNOS. Representative erectile responses to cavernosal nerve stimulation in young rats, AdRSVbgal-transfected aged rats, and AdRSVeNOS-transfected aged rats 5 days after administration of the viruses are shown in Figure 5 . The magnitude of the increase in cavernosal pressure after cavernosal nerve stimulation (5 V) in the aged rat transfected with AdRSVb gal was signi®cantly lower (P`0.05) than the young rat, while those rats transfected with the adenoviral gene encoding for eNOS had an increase in cavernosal pressure after cavernosal nerve stimulation (5 V) which was similar to the young rats ( Figure 5 ). The magnitude of erectile responses to cavernosal nerve stimulation in vehicle-treated aged rats and those treated with AdRSVbgal were similar (data not shown). The magnitude of the increase in cavernosal pressure in response to cavernosal nerve stimulation ranging from 5 to 7.5 V was increased signi®cantly (P`0.05) 5 days after treatment with AdRSVeNOS when compared to responses 5 days after administration of AdRSVbgal ( Figure 6 ). The increase in cavernosal pressure in the AdRSVeNOStransfected aged rats was similar to young control rats at both 5 and 7.5 V (Figure 6 ). The responses were reproducible at both voltage ranges 30 min after the initial stimulation. There was no detectable difference (P b 0.05) in resting intracavernosal pressure (mmHg) and systemic arterial pressure (mmHg) among the three experimental groups. The values for mean intracavernosal pressure and systemic arterial pressure, respectively, were 13.6 AE 1.8 and 108 AE 3.7 mmHg for the young rats (n 8), 12.6 AE 1.1 and 112 AE 3.5 mmHg for AdRSVbgal-transfected aged rats (n 10), and 11.2 AE 1.0 and 114 AE 3.4 mmHg for AdRSVeNOS-transfected aged rats (n 10). 
Histological analysis
Five days after intracavernosal injection of AdRSVeNOS, examination of the penises showed a few polymorphonuclear neutrophils, which suggests that a local in¯ammatory response was present ( Figure 7) . The vehicle-treated rats had no polymorphonuclear neutrophils present. Normal histological patterns and tissue architecture of the penis as a whole were preserved after transfection with AdRSVeNOS and vehicle, suggesting that the adenovirus itself or injection with a needle did not cause traumatic changes in the rat penis ( Figure 7) .
Discussion
This study demonstrates that adenoviral-mediated transfer of the eNOS gene to the aged rat penis increases cavernosal levels of eNOS protein, eNOS mRNA and cGMP which causes physiologically relevant changes in erectile function without any observable adverse effects. These data imply that eNOS transgene has biological activity in the rat penis and can reverse the age-related erectile dysfunction associated with reduction of NO Figure 5 Representative time course of changes in intracavernosal pressure during cavernosal nerve stimulation (5 V) for young rats (20 weeks; squares), aged rats (60 weeks) transfected with AdRSVbgal (diamonds), and aged rats (60 weeks) transfected with AdRSVeNOS (circles). In vivo erection experiments were conducted 5 days after transfection with the adenoviruses in the aged rat. Figure 6 Bar graphs showing the increase in intracavernosal pressure in response to cavernosal nerve stimulation (5 and 7.5 V) in young rats (20 weeks) and aged rats (60 weeks) transfected with AdRSVbgal and AdRSVeNOS. In vivo erection experiments were conducted 5 days after transfection with the adenoviruses in the aged rat. n indicates number of experiments; *response signi®-cantly different from young rats (P`0.05); **response signi®-cantly different from aged rats transfected with AdRSVbgal (P`0.05). synthesis in the NANC penile nerve ®bers andaor vascular endothelium of the penis.
Somatic gene therapy can be de®ned as the ability to introduce genetic material into an appropriate cell type in vivo, thus altering gene expression of that cell in order to produce a therapeutic effect. Gene therapy for the treatment of human disease can be accomplished through a number of different approaches. 22 ± 24 In order to transfer genetic material to a variety of cells, DNA or RNA must be delivered in a vehicle or vector that allows ef®cient gene transfer. Some examples of vectors used to date for gene transfer include non-viral liposomes, naked DNA, and viral adenoviruses, adeno-associated viruses and retroviruses. 22 One advantage of adenoviruses is that they can infect a wide variety of replicating and nonreplicating cell types in vitro and in vivo. In particular, these vectors can ef®ciently transfect vascular endothelial and smooth muscle cells. 25, 26 However, they have also been shown to cause host in¯ammatory and immune responses that shorten the duration of gene expression in vivo. 27 Any successful gene therapy approach to human disease requires a therapeutic gene. NO plays a primary role in the process of penile erection. 4, 6 It is synthesized by the conversion of L-arginine into L-citrulline by NOS. A reduction of NOS has been shown to occur in aging, and administration of L-arginine, the substrate of NOS, improves erectile responses in the aged rat. 9, 11, 28 Furthermore, Burnett and colleagues have shown that mice lacking the gene for neuronal NOS do not have impaired erectile function, suggesting that the endothelial NOS isoform plays a vital role in the physiology of erection. 29 Taken together, one can anticipate that gene transfer of eNOS would be bene®cial for the treatment of erectile dysfunction associated with aging.
Gene therapy for the treatment of human diseases such as atherosclerosis, congestive heart failure, neurodegenerative diseases, genetic disorders and cancer has been employed with the hope of curing these disease processes 22 ± 24,30 It has been suggested that the penis is an ideal organ for the use of gene therapy because of its external location, easy accessibility and the low turnover rate of vascular smooth muscle cells, thus allowing a desired gene to be expressed for long periods of time without affecting the systemic circulation. 31 Several researchers have envisioned the use of gene therapy for the treatment of erectile dysfunction. Garban and associates ®rst demonstrated that gene therapy can be performed in the penis by utilizing naked cDNA encoding the penile inducible nitric oxide synthase gene. 16 They demonstrated an improvement in erectile function in aged rats after injection with RPiNOS. 16 Christ and colleagues later showed that injection of hSIo cDNA, which encodes the human smooth muscle maxi-K channel, into the rat corpora cavernosa can increase gap junction formation and enhance erectile responses to nerve stimulation in the aged rat. 14 These innovative studies provide evidence that in vivo gene transfer can have bene®cial physiological effects on penile erection.
More recently, our laboratory reported that adenoviral gene transfer of eNOS can reverse agerelated erectile dysfunction in rats. 17 However, in that study we used an adenovirus which had limited activity of expression of the eNOS gene, requiring repeated injections into the penis, which in turn could injure the vascular smooth muscle cells of the penis or, more importantly, cause a host-immune response. In the present study, instead of the cytomegalovirus promoter, we utilized the rous sarcoma promoter, which has been shown to exhibit a longer sustained duration of expression of a desired gene. 32 A signi®cant observation from this study is that adenovirus-mediated gene transfer of b-galactosidase when driven by the rous sarcoma promoter can have sustained expression for up to 30 days in the corpora cavernosa of the rat. Moreover, 5 days after intracavernosal injection of AdRSVeNOS into the rat corpora, there was an age-related reversal of erectile dysfunction. Aged rats (60 weeks) transfected with AdRSVbgal had a signi®cantly lower erectile function than the younger rat (20 weeks) population. However, 5 days after transfection with AdRSVeNOS, the aged rats (60 weeks) increased their intracavernosal pressure, as determined by cavernosal nerve stimulation, to a level similar to those of younger rats at all voltage settings. Consistent with this observation, there was an increase in eNOS protein, cGMP and mRNA levels, as determined by Western blot and RT-PCR techniques, at a time when cavernosal nerve-stimulated erectile responses are increased, indicating that the increase in erectile response was due to increased NO production. The speci®c cell types (endothelial or vascular smooth muscle cells) to which the eNOS gene was incorporated are unknown and will be the focus of future research efforts. In these experiments, erectile response was only assessed 5 days after transfection with the eNOS gene; however, it is likely that the erectile response would be augmented for longer periods of time, as witnessed by the sustained expression of b-galactosidase in the rat corpora cavernosa after transfection with the AdRSVb gal virus. These data provide strong evidence that adenoviral gene transfer of eNOS can cause physiologically relevant changes in erectile responses in the aged rat.
Adenoviral vectors can infect a wide variety of cell types in vivo, and host in¯ammatory and immune responses are common. It is conceivable that adenoviral-mediated gene transfer to the rat penis can induce an in¯ammatory response, which would increase levels of inducible nitric oxide synthase. However, several observations suggest that an in¯ammatory response did not occur. (1) There was no increase in cGMP levels in cavernosal tissue transfected with AdRSVbgal, a vector devoid of vascular activity; (2) there was no increase in iNOS protein expression in the AdRSVbgal and AdRSVeNOS-transfected animals; (3) there were no overt signs of an in¯ammatory response in animals treated with AdRSVbgal or AdRSVeNOS under the conditions of the present experiment. White blood cell and lymphocyte counts in serum samples from animals treated with vehicle (6.8 AE 0.3 kaml and 4.9 AE 0.5 kaml, respectively) and AdRSVeNOS (6.7 AE 0.4 kaml and 4.6 AE 0.2 kaml, respectively) were similar (P b 0.05). Histological examination of the penises from animals treated with AdRSVeNOS demonstrated only a small number of polymorphonuclear neutrophils, which suggests only a minor local in¯ammatory response. This minor in¯amma-tory response did not alter cavernosal tone or responsiveness 5 days after transfection.
Conclusion
In summary, the results of the present study demonstrate that adenoviral-mediated transfer of the eNOS gene can increase eNOS protein, cGMP and eNOS mRNA in the corpora cavernosa of the aged rat penis. Moreover, over-expression of eNOS enhances the erectile response to cavernosal nerve stimulation. These results support the hypothesis that in vivo gene transfer of NOS isoforms and K channel openers can augment the erectile response to nerve stimulation in the aged rat. 14, 16 It is reasonable to assume that NOS will become an important target gene for gene therapy strategy because of its vital pharmacological role in the process of penile erection. These data suggest that adenoviral mediated transfer of the eNOS gene or other NOS isoforms may represent an exciting new form of therapy for the treatment of male erectile dysfunction. With innovations being made in the development of new vectors which have greater ef®ciency and stability of transduction and fewer unwanted side effects, gene therapy is an exciting opportunity to be explored for the future management of erectile dysfunction.
